Personalis Inc (PSNL) Stock Price, Quote & News

Company Profile

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor an...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 650 752 1300

Fax: 650 752 1301

Website: www.personalis.com

Address:

6600 Dumbarton Circle, Fremont, United States

arribaStocktrading Jul. 3 at 1:16 PM

$PSNL I think we are being cheated out of another new 52-week high by the market being closed today!

0 · Reply

MorganHoratio Jul. 2 at 9:57 PM

One of the strongest sectors outside of AI right now is Biotech. Oncology $PSNL Personalis $GH Guardant Health $NEO NeoGenomics $INCY Incyte Non-AI capital flows heavily into precision oncology and screening tech! Smart money triggers tactical limit entries atop long-term FIB volume floors, lock-floating diagnostic monopolies. Early-screening king GH leads the breakout on explosive Shield revenue and full-year guidance upgrades, while path-leader NEO secures NGS pathology profitability and PSNL firms up technical entries. Flanking them, biopharma vanguard INCY hardens its valuation ceiling following key European Opzelura backing. Clinical execution means nothing without scalable adoption and margins. Facing this oncology rotation, are you buying the FIB support floors or holding defensive cash? Drop your execution playbook below!

1 · Reply

BioTechNoir Jul. 2 at 7:34 PM

$PSNL go green baby!!

0 · Reply

AnniyanS Jul. 2 at 6:57 PM

$PSNL Feeling compelled to say $PSNL will be over $15 next week.

0 · Reply

degeneratetrader23 Jul. 2 at 6:09 PM

$PSNL a lot of hot small caps are getting torched today. This is very promising price action here. I think we're gonna break out of resistance next week.

0 · Reply

BioTechNoir Jul. 2 at 3:51 PM

$PSNL low volume, keeping most gains. you guys reading this as consolidation or ??

1 · Reply

arribaStocktrading Jul. 1 at 8:41 PM

$PSNL Tempus rising but they can't join our Magnificent club without making new highs first. A cloud that hangs over Tempus relates to lawsuits concerning patient privacy with regard to their data collection efforts. There's a lot of resistance with regard to sharing personal medical records. But if the data is anonymized , that should alleviate concerns but we shall see.

0 · Reply

LucienW Jul. 1 at 6:36 PM

$PSNL imo right now our SP is caught in a rather awkward place. On one hand it’s valued at over 20x TTM revenue, at the high end of our peers and on par with GH yet without any past revenue growth to back it up; on the other hand, we can argue that our past revenues are not exactly relevant here for apparent reasons yet the FY26 guidance isn’t exactly encouraging, so far; We can argue that the (rate of test volume growth) x (increasing coverage percentage) have the potential for exponential top line growth but the management has been silent about the guidance even after all the approvals in the past few months. I don’t know about you guys but I’m very nervous about the upcoming ER. It could be a make or break moment for us.

3 · Reply

Cambodia22 Jul. 1 at 5:04 PM

$PSNL popped. Turning point im out

0 · Reply

OptionRunners Jul. 1 at 4:54 PM

$PSNL January 2027 call buyer with a big spike in IV on it

1 · Reply

Personalis’ specimen collection kits obtain European Union CE-IVD mark

Jun 9, 2026, 6:00 AM EDT - 25 days ago

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

Jun 2, 2026, 6:00 AM EDT - 4 weeks ago

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

May 26, 2026, 6:00 AM EDT - 5 weeks ago

Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

2026-05-20T10:10:56.000Z - 6 weeks ago

Personalis secures fourth Medicare coverage decision for NeXT Personal

May 20, 2026, 6:00 AM EDT - 6 weeks ago

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

May 14, 2026, 4:01 PM EDT - 7 weeks ago

Personalis to Participate in Upcoming Investor Events

2026-05-13T10:27:16.000Z - 7 weeks ago

Personalis announces that CMS program expanded coverage for NeXT

May 13, 2026, 6:00 AM EDT - 7 weeks ago

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

May 12, 2026, 12:00 PM EDT - 7 weeks ago

Personalis Transcript: AGM 2026

2026-05-12T15:08:02.000Z - 7 weeks ago

Personalis price target lowered to $9 from $10 at Morgan Stanley

2026-05-11T12:19:55.000Z - 7 weeks ago

Personalis price target lowered to $11 from $13 at BTIG

2026-05-07T22:45:48.000Z - 2 months ago

Personalis files automatic mixed securities shelf

2026-05-07T21:26:54.000Z - 2 months ago

Personalis reports Q1 EPS (29c), consensus (27c)

2026-05-07T21:25:28.000Z - 2 months ago

Personalis affirms FY26 revenue view of $78M-$80M, consensus $78.8M

May 7, 2026, 5:00 PM EDT - 2 months ago

Personalis Earnings Call Transcript: Q1 2026

May 7, 2026, 5:00 PM EDT - 2 months ago

Personalis Earnings release: Q1 2026

May 7, 2026, 5:00 PM EDT - 2 months ago

Personalis Quarterly report: Q1 2026

May 7, 2026, 4:01 PM EDT - 2 months ago

Personalis Reports First Quarter Results and Recent Highlights

2026-05-05T15:25:38.000Z - 2 months ago

Personalis management to meet virtually with Lake Street

Apr 23, 2026, 4:01 PM EDT - 2 months ago

Personalis to Announce First Quarter 2026 Financial Results

Apr 21, 2026, 6:00 AM EDT - 2 months ago

Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026

Apr 13, 2026, 6:00 AM EDT - 2 months ago

Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Personalis Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Personalis Proxy statement: Proxy filing

Apr 1, 2026, 4:01 PM EDT - 3 months ago

Personalis to Participate in the 25th Annual Needham Virtual Conference

2026-03-17T20:15:19.000Z - 3 months ago

Personalis names Richard Chen president

Mar 17, 2026, 4:00 PM EDT - 3 months ago

Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption

2026-03-12T10:16:13.000Z - 4 months ago

Personalis’ NeXT Personal test shows predictive efficacy in breast cancer

Mar 12, 2026, 6:00 AM EDT - 4 months ago

Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®

2026-03-05T14:28:06.000Z - 4 months ago

Personalis price target lowered to $10 from $11 at Morgan Stanley

Feb 26, 2026, 5:00 PM EST - 4 months ago

Personalis Earnings Call Transcript: Q4 2025

Feb 26, 2026, 5:00 PM EST - 4 months ago

Personalis Annual report: Q4 2025

Feb 26, 2026, 5:00 PM EST - 4 months ago

Personalis Earnings release: Q4 2025

2026-02-26T21:47:54.000Z - 4 months ago

Personalis sees FY26 revenue $78M-$80M, consensus $81.7M

2026-02-26T21:18:27.000Z - 4 months ago

Personalis reports Q4 EPS (26c), consensus (28c)

Feb 26, 2026, 4:01 PM EST - 4 months ago

Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

Feb 17, 2026, 4:01 PM EST - 4 months ago

Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference

Feb 12, 2026, 4:01 PM EST - 5 months ago

Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

2026-02-10T11:21:43.000Z - 5 months ago

Personalis’ MRD test receives Medicare coverage in lung cancer surveillance

Feb 10, 2026, 6:00 AM EST - 5 months ago

Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance

2026-02-02T11:10:08.000Z - 5 months ago

Personalis announces publication of new study on NeXT Personal

Feb 2, 2026, 6:00 AM EST - 5 months ago

Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors

Jan 28, 2026, 4:01 PM EST - 5 months ago

Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

2026-01-26T14:41:40.000Z - 5 months ago

Personalis price target raised to $13 from $12 at Guggenheim

Jan 12, 2026, 4:00 PM EST - 6 months ago

Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™

2026-01-08T13:26:40.000Z - 6 months ago

Personalis sees FY25 revenue $69M-$70M, consensus $69.96M

Jan 8, 2026, 8:00 AM EST - 6 months ago

Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights

Dec 17, 2025, 6:00 AM EST - 7 months ago

Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

Dec 11, 2025, 9:00 AM EST - 7 months ago

New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer

Nov 18, 2025, 4:01 PM EST - 8 months ago

Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 8 months ago

Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

Nov 4, 2025, 5:00 PM EST - 8 months ago

Personalis Earnings Call Transcript: Q3 2025

Nov 4, 2025, 5:00 PM EST - 8 months ago

Personalis Quarterly report: Q3 2025

Nov 4, 2025, 5:00 PM EST - 8 months ago

Personalis Earnings release: Q3 2025

Nov 4, 2025, 4:01 PM EST - 8 months ago

Personalis Reports Third Quarter 2025 Financial Results

Oct 21, 2025, 4:01 PM EDT - 9 months ago

Personalis to Announce Third Quarter 2025 Financial Results

Oct 16, 2025, 9:00 AM EDT - 9 months ago

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

Sep 15, 2025, 5:35 PM EDT - 10 months ago

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 10, 2025, 4:05 PM EDT - 10 months ago

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

Sep 3, 2025, 4:05 PM EDT - 10 months ago

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

Aug 27, 2025, 4:01 PM EDT - 11 months ago

Personalis to Participate in Upcoming Investor Conferences

Aug 5, 2025, 5:00 PM EDT - 11 months ago

Personalis Earnings Call Transcript: Q2 2025

Aug 5, 2025, 5:00 PM EDT - 11 months ago

Personalis Earnings release: Q2 2025

Aug 5, 2025, 5:00 PM EDT - 11 months ago

Personalis Quarterly report: Q2 2025

Aug 5, 2025, 4:01 PM EDT - 11 months ago

Personalis Reports Second Quarter 2025 Financial Results

Jul 22, 2025, 4:01 PM EDT - 1 year ago

Personalis to Announce Second Quarter 2025 Financial Results

Jul 9, 2025, 4:00 PM EDT - 1 year ago

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

TEM

Jun 3, 2025, 4:00 PM EDT - 1 year ago

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

Jun 2, 2025, 4:00 PM EDT - 1 year ago

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

May 22, 2025, 6:00 AM EDT - 1 year ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

May 14, 2025, 4:01 PM EDT - 1 year ago

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 6, 2025, 5:00 PM EDT - 1 year ago

Personalis Earnings Call Transcript: Q1 2025

May 6, 2025, 5:00 PM EDT - 1 year ago

Personalis Quarterly report: Q1 2025

May 6, 2025, 5:00 PM EDT - 1 year ago

Personalis Earnings release: Q1 2025

May 6, 2025, 4:01 PM EDT - 1 year ago

Personalis Reports First Quarter 2025 Financial Results

Apr 28, 2025, 5:00 PM EDT - 1 year ago

Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study

Apr 22, 2025, 4:01 PM EDT - 1 year ago

Personalis to Announce First Quarter 2025 Financial Results

Apr 22, 2025, 6:00 AM EDT - 1 year ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Personalis Proxy statement: Proxy Filing

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Personalis Proxy statement: Proxy Filing

Mar 26, 2025, 4:01 PM EDT - 1 year ago

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

Mar 3, 2025, 6:00 AM EST - 1 year ago

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Feb 27, 2025, 5:00 PM EST - 1 year ago

Personalis Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

Personalis Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

Personalis Earnings release: Q4 2024

Feb 27, 2025, 4:01 PM EST - 1 year ago

Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 7:00 AM EST - 1 year ago

Personalis Registration statement: Registration Filing

Feb 18, 2025, 4:01 PM EST - 1 year ago

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference

Feb 13, 2025, 4:01 PM EST - 1 year ago

Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results

Jan 28, 2025, 4:01 PM EST - 1 year ago

Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 13, 2025, 5:00 AM EST - 1 year ago

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

arribaStocktrading Jul. 3 at 1:16 PM

$PSNL I think we are being cheated out of another new 52-week high by the market being closed today!

0 · Reply

MorganHoratio Jul. 2 at 9:57 PM

1 · Reply

BioTechNoir Jul. 2 at 7:34 PM

$PSNL go green baby!!

0 · Reply

AnniyanS Jul. 2 at 6:57 PM

$PSNL Feeling compelled to say $PSNL will be over $15 next week.

0 · Reply

degeneratetrader23 Jul. 2 at 6:09 PM

$PSNL a lot of hot small caps are getting torched today. This is very promising price action here. I think we're gonna break out of resistance next week.

0 · Reply

BioTechNoir Jul. 2 at 3:51 PM

$PSNL low volume, keeping most gains. you guys reading this as consolidation or ??

1 · Reply

arribaStocktrading Jul. 1 at 8:41 PM

0 · Reply

LucienW Jul. 1 at 6:36 PM

3 · Reply

Cambodia22 Jul. 1 at 5:04 PM

$PSNL popped. Turning point im out

0 · Reply

OptionRunners Jul. 1 at 4:54 PM

$PSNL January 2027 call buyer with a big spike in IV on it

1 · Reply

Skibum77 Jul. 1 at 4:31 PM

$PSNL wait till the squeeze starts :)

0 · Reply

BioTechNoir Jul. 1 at 4:16 PM

$PSNL NICE

0 · Reply

arribaStocktrading Jul. 1 at 3:38 PM

$PSNL The Magnificent 4 (PANG) all making new 52-week highs today. Natera's 52-week high is also their all-time high. We've got a LONG way to go to get back to our ATH.

1 · Reply

arribaStocktrading Jul. 1 at 2:32 PM

$PSNL This is what Goldilocks look like: Bullish but not extended. Very healthy stock rotation in progress.

0 · Reply

arribaStocktrading Jul. 1 at 2:03 PM

$PSNL Climb Baby Climb!

0 · Reply

RockyMontana Jul. 1 at 1:30 AM

$PSNL now everyone wants a pullback but it aint giving ya. 😉

0 · Reply

ExNoose Jun. 30 at 11:48 PM

$PSNL 730k after hours?

0 · Reply

LucienW Jun. 30 at 9:40 PM

$PSNL huge volume after market today. I got a feeling the coming 13F’s are gonna be pretty exciting

0 · Reply

LukasWo Jun. 30 at 8:34 PM

$PSNL am I the only one finding the CFO's latest sale of 4982 shares amusing? https://investors.personalis.com/static-files/20eadbe3-187c-4ca7-a6bd-a36e6f43e734

2 · Reply

degeneratetrader23 Jun. 30 at 2:37 PM

$PSNL oomph. nice recovery.

0 · Reply

ChurxyChurx Jun. 30 at 12:42 PM

$PSNL what is the bull case here? i see EPS next Y 12.43% which is not high enough for me to buy. what am i missing?

4 · Reply

ExNoose Jun. 30 at 9:37 AM

$PSNL Personalis against his peers

1 · Reply

Market Cap	1.43B
Revenue (ttm)	69.65M
Net Income (ttm)	-81.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-116.68%
Debt to Equity Ratio	0.00

Volume	3,788,600
Avg Vol	3,119,040
Day's Range	N/A - N/A
Shares Out	104.72M
Stochastic %K	86%
Beta	2.24
Analysts	Strong Sell
Price Target	$10.86